drugset
drugset / Trial / NCT02566369

Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

NCT02566369 ↗

Phase 3 Completed 1208 enrolled Galderma R&D
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.

Timeline

Start
2015-11-30
Primary completion
2017-11-14
Completion
2017-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Trifarotene Small molecule 50 unknown —

Indications

acne